- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00523185
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
August 29, 2007 updated by: Stanford University
The purpose of this study is to compare the efficacy of two commonly used medications in the treatment of alcohol withdrawal, diazepam and lorazepam.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Despite the frequent use of benzodiazepines for the treatment of alcohol withdrawal, studies comparing the efficacy of long and short half-life benzodiazepines in the treatment of alcohol withdrawal have shown mixed results.
Due to the conflicting nature of published reports, clinicians have no clear indication as to which type of agent is preferable.
The purpose of this study is to compare the efficacy of two commonly accepted medications in the treatment of alcohol withdrawal, diazepam and lorazepam, which are long and short half-life benzodiazepines, respectively.
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Palo Alto Veterans Affairs Hospital System
-
Stanford, California, United States, 94305
- Stanford Hospital and Clinics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of alcohol withdrawal
- History of alcohol use within 24 hours
- Ability to consent to participate in the study
Exclusion Criteria:
- Unwillingness to participate in the study
- Active abuse of other CNS depressants
- Acute intoxication with a CNS activating agent
- Severe hepatic dysfunction
- Pregnancy
- History of dementia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
|
Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses.
Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
Other Names:
|
Active Comparator: 1
|
Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measures include serial measures of vital signs and scores on the Clinical Institute Withdrawal Assessment for Alcohol-Revised scale (CIWA-Ar), a widely used scale that monitors alcohol withdrawal symptoms.
Time Frame: one to two weeks
|
one to two weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome measures include total benzodiazepine use.
Time Frame: one to two weeks
|
one to two weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jose R Maldonado, MD, Stanford University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2003
Study Completion (Actual)
November 1, 2004
Study Registration Dates
First Submitted
August 29, 2007
First Submitted That Met QC Criteria
August 29, 2007
First Posted (Estimate)
August 31, 2007
Study Record Updates
Last Update Posted (Estimate)
August 31, 2007
Last Update Submitted That Met QC Criteria
August 29, 2007
Last Verified
August 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Neuromuscular Agents
- Muscle Relaxants, Central
- Diazepam
- Lorazepam
Other Study ID Numbers
- 77757
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Withdrawal
-
VA Salt Lake City Health Care SystemCompleted
-
Denver Health and Hospital AuthorityTerminatedAlcohol Withdrawal Delirium | Alcohol Withdrawal Associated Autonomic Hyperactivity | Alcohol Withdrawal Hallucinosis | Alcohol Withdrawal-Induced Delirium TremensUnited States
-
University of Colorado, DenverWithdrawnAlcohol WithdrawalUnited States
-
Unity Health TorontoTerminatedAlcohol Withdrawal | Alcohol Withdrawal Delirium | Alcohol Withdrawal SeizuresCanada
-
Medical University of ViennaCompletedPsychophysiologic Reaction | Alcohol WithdrawalAustria
-
University Hospital, MontpellierCompletedAddiction | Alcohol Use Disorder | Alcohol Withdrawal SyndromeFrance
-
Jubilee Mission Medical College and Research InstituteINCRE fellowship from DBT, govt of IndiaCompletedAlcohol Withdrawal Symptoms | Delirium Tremens (DTs)
-
Jonathan RosensonAlameda County Medical CenterCompleted
-
Yale UniversityRecruiting
-
Catholic University of the Sacred HeartMedical University of Vienna; University of Bologna; CT Pharmaceutical Industries...CompletedAlcohol Dependence | Alcohol Withdrawal SyndromeAustria, Italy
Clinical Trials on Diazepam
-
University of MonastirNot yet recruiting
-
Eisai Inc.CompletedLymphoma, B-CellUnited States
-
Jason GilleranTerminatedMetabolism, DrugUnited States
-
University of CincinnatiCompleted
-
University of PittsburghNational Institute on Drug Abuse (NIDA)Completed
-
Acorda TherapeuticsCompleted
-
Acorda TherapeuticsTerminatedRefractory EpilepsyUnited States
-
Aquestive TherapeuticsSyneos Health; CovanceCompletedEpilepsyUnited States
-
Mayo ClinicCompletedMyocardial Reperfusion InjuryUnited States
-
Institute of Mental Health, SingaporeSingapore Clinical Research InstituteCompletedOpiate Dependent Patients Who Are Undergoing Inpatient Detoxification in SingaporeSingapore